On Monday, Bionano Genomics Inc (NASDAQ: BNGO) was -3.84% drop from the session before settling in for the closing price of $0.33. A 52-week range for BNGO has been $0.30 – $2.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 32.87% over the past five years. When this article was written, the company’s average yearly earnings per share was at 83.44%. With a float of $85.45 million, this company’s outstanding shares have now reached $86.00 million.
Let’s look at the performance matrix of the company that is accounted for 344 employees. In terms of profitability, gross margin is 28.97%, operating margin of -493.88%, and the pretax margin is -557.95%.
Bionano Genomics Inc (BNGO) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Bionano Genomics Inc stocks. The insider ownership of Bionano Genomics Inc is 0.64%, while institutional ownership is 11.55%.
Bionano Genomics Inc (BNGO) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -3.22 earnings per share (EPS) during the time that was less than consensus figure (set at -0.97) by -2.25. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 83.44% per share during the next fiscal year.
Bionano Genomics Inc (NASDAQ: BNGO) Trading Performance Indicators
You can see what Bionano Genomics Inc (BNGO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.01, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.48 in one year’s time.
Technical Analysis of Bionano Genomics Inc (BNGO)
Bionano Genomics Inc (NASDAQ: BNGO) saw its 5-day average volume 3.09 million, a positive change from its year-to-date volume of 1.62 million. As of the previous 9 days, the stock’s Stochastic %D was 16.62%. Additionally, its Average True Range was 0.04.
During the past 100 days, Bionano Genomics Inc’s (BNGO) raw stochastic average was set at 2.58%, which indicates a significant decrease from 11.08% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.36% in the past 14 days, which was lower than the 86.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4384, while its 200-day Moving Average is $0.8346. Nevertheless, the first resistance level for the watch stands at $0.3453 in the near term. At $0.3702, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.3873. If the price goes on to break the first support level at $0.3033, it is likely to go to the next support level at $0.2862. Assuming the price breaks the second support level, the third support level stands at $0.2613.
Bionano Genomics Inc (NASDAQ: BNGO) Key Stats
There are 66,857K outstanding shares of the company, which has a market capitalization of 27.56 million. As of now, sales total 36,120 K while income totals -232,490 K. Its latest quarter income was 7,770 K while its last quarter net income were -16,220 K.
